About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Liver Disease Clinical Trials | 201 Studies Recruiting

Clinical TrialsLiver Disease

Liver Disease Clinical Trials

Browse 201 clinical trials for liver disease. Find studies that match your criteria and connect with research centers.

Find trials near:

New York Los Angeles Chicago Houston Phoenix Philadelphia

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 1-20 of 201 trials

RecruitingA Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASHThe purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of efimosfermin in participants with metabolic dysfunction…NCT06920043·Chandler, Arizona and 29 others UnknownImpact of Fluid Status on Liver Elastography and T1-mapping Results in Patients Undergoing CMR.Correlation between CMR T1-times, liver T1-times, fibroscan and fluid status to identify the correlation and pathogenesis of liver disease in patients with heart disease.NCT05239260·Vienna

Related Searches

cirrhosistrials nafldtrials

Data from ClinicalTrials.govTerms

UnknownLiver Fibrosis in Peri-menopausal WomenThis is a prospective observational study in a single medical center.NCT03602573·Taoyuan

CompletedStudy in Healthy Adults Evaluating PF-07202954The study is planned as a 3 part design with investigator and participant blinded (sponsor-open), placebo controlled, randomized, dose escalation in Part 1 and Part 2; and a…NCT04857437·New Haven, Connecticut

RecruitingA Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASHThe study will assess the efficacy and safety of pegozafermin administered in participants with compensated cirrhosis due to MASH (biopsy-confirmed fibrosis stage F4 MASH…NCT06419374·Birmingham, Alabama and 325 others

CompletedEffect of Anti-osteoporotic Medications on Nonalcoholic Fatty Liver DiseaseNonalcoholic fatty liver disease (NAFLD) is a chronic, metabolic liver disease that is closely related to obesity, type 2 diabetes mellitus (T2DM) and metabolic syndrome (MetS) in…NCT05493761·Thessaloniki and 2 others

TerminatedClinical Study In Infants With Rapidly Progressive Lysosomal Acid Lipase DeficiencyThis was an open-label, repeat-dose, study of sebelipase alfa in infants with rapidly progressive lysosomal acid lipase deficiency (LAL-D).NCT02193867·Phoenix, Arizona and 4 others

Active not recruitingSimultaneous Quantification of Liver Fat Content, Fatty Acid Composition, and Fibrosis Using Spin-lock MRI for Steatohepatitis AssessmentNon-alcoholic fatty liver disease is a major health problem worldwide. It includes simple steatosis and NASH which has inflammation in the liver, with or without fibrosis.NCT05384652·Hong Kong, Shatin

UnknownClinical Application of Non-invasive Assessment for Staging Liver Steatosis and Liver FibrosisNowadays, the morbidity of Nonalcoholic fatty liver disease (NAFLD) show ascending trend year by year, which has become an important public health problem in China.NCT03386890·Beijing, Beijing Municipality

Active not recruitingA Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and FibrosisA double-blind placebo controlled randomized Phase 3 study to determine if 80 or 100 mg of MGL-3196 as compared with placebo resolves NASH and/or reduces fibrosis on liver biopsy…NCT03900429·Birmingham, Alabama and 246 others

CompletedAssessing Kids for Liver Inflammation and Fibrosis Using Non-invasive MRIThis is a prospective observational study which will recruit up to 100 paediatric participants over a period of 30 months to determine whether MRI is as accurate at detecting…NCT03198104·Warsaw

CompletedStudy Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic SteatohepatitisThe primary objective of this study is to evaluate whether obeticholic acid (OCA; INT-747) can lead to histological improvement in fibrosis with no worsening of NASH in adults…NCT03439254·Dothan, Alabama and 191 others

RecruitingEstablishment of NAFLD Cohort and Development of Fibrosis MarkersThis study is designed for establishment of non-alcoholic fatty liver disease patients cohort to development of markers to predict histologic progression of liver fibrosis.NCT02206841·Seoul

RecruitingMetabolic Phenotyping and Follow-Up of Patients With and Without Diabetes After New Onset of STEMIThe aim of the prospective observational DISTEMI-Study in people with and without Diabetes mellitus (DI) after new onset of ST-Segment Elevation Myocardial Infarction (STEMI) aged…NCT05046483·Düsseldorf, North Rhine-Westphalia

CompletedClearance of NRL972 in Patients With Cirrhosis, Nonalcoholic Steatohepatitis (NASH) and in Healthy VolunteersThe study was conducted to describe and compare the plasma pharmacokinetics of NRL972 administered after a standard meal and while fasted in patients with hepatic cirrhosis…NCT00856869·Sofia

RecruitingThyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in VeteransNonalcoholic steatohepatitis (NASH) is the aggressive form of nonalcoholic fatty liver disease, which is rapidly becoming a worldwide public health problem.NCT05526144·Columbia, Missouri

RecruitingCardiac Dysfunction in Patients with Fatty Liver DiseaseCirrhotic cardiomyopathy is seen as a blunted contractile responsiveness to stress, and/or altered diastolic relaxation with electrophysiological abnormalities, in absence of…NCT06386094·Chandigarh, Chandigarh

CompletedA Self Selected Population Study of Undiagnosed NAFLD and NASH, Using an Echosens FibroScan, in at Risk PopulationsLiver disease (NAFLD) and (NASH) are a rapidly increasing population health threat driven primarily by diet and lifestyle.NCT03726827·Texas City, Texas

Active not recruitingEffect of a GnRH Analog on Hepatic SteatosisMenopause increases the risk of metabolic dysfunction-associated steatotic liver disease (MASLD), possibly owing to the abrupt lack of estrogen.NCT06523530·Thessaloniki, Thessaloniki and 1 other

Not yet recruitingWearable Patch Ultrasound Probe for Diagnosis of Liver StiffnessLiver stiffness measurement is a key non-invasive tool for assessing liver fibrosis and cirrhosis in patients with chronic liver disease.NCT07716384

Page 1 of 11Next